|
|
Blood, 1 April 2008, Vol. 111, No. 7, pp. 3751-3759.
Prepublished online as a Blood First Edition Paper on January 23, 2008; DOI 10.1182/blood-2007-07-102186.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Gerlinde Wernig1,
Jeffrey R. Gonneville2,
Brian J. Crowley2,
Margret S. Rodrigues1,2,
Mamatha M. Reddy1,2,
Heidi E. Hudon2,
Christoph Walz2,
Andreas Reiter3,
Klaus Podar1,2,
Yohan Royer4,
Stefan N. Constantinescu4,
Michael H. Tomasson5,
James D. Griffin1,2,
D. Gary Gilliland1, and
Martin Sattler1,2
1 Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA;
2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
3 III Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany;
4 Ludwig Institute for Cancer Research, Brussels, Belgium; and
5 Department of Medicine, Washington University School of Medicine, St Louis, MO
The V617F activating point mutation in Jak2 is associated with a proportion of myeloproliferative disorders. In normal hematopoietic cells, Jak2 signals only when associated with a growth factor receptor, such as the erythropoietin receptor (EpoR). We sought to identify the molecular requirements for activation of Jak2V617F by introducing a point mutation in the FERM domain (Y114A), required for receptor binding. Whereas BaF3.EpoR cells are readily transformed by Jak2V617F to Epo independence, we found that the addition of the FERM domain mutation blocked transformation and the induction of reactive oxygen species. Further, while cells expressing Jak2V617F had constitutive activation of STAT5, cells expressing Jak2V617F/Y114A did not, suggesting that signaling is defective at a very proximal level. In addition, expression of the Myc and Pim proto-oncogenes by Jak2V617F was found to be FERM domain dependent. An inducible constitutively active STAT5 mutant expressed in BaF3 cells was sufficient to induce Myc and Pim. Finally, the FERM domain in Jak2V617F was also required for abnormal hematopoiesis in transduced primary murine fetal liver cells. Overall, our results suggest that constitutive activation of Jak2 requires an intact FERM domain for a transforming phenotype, and is necessary for activation of the major target of Jak2, STAT5.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. S. Fernandes, M. M. Reddy, J. R. Gonneville, S. C. DeRoo, K. Podar, J. D. Griffin, D. M. Weinstock, and M. Sattler
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair
Blood,
August 27, 2009;
114(9):
1813 - 1819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Hercus, D. Thomas, M. A. Guthridge, P. G. Ekert, J. King-Scott, M. W. Parker, and A. F. Lopez
The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease
Blood,
August 13, 2009;
114(7):
1289 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gery, Q. Cao, S. Gueller, H. Xing, A. Tefferi, and H. P. Koeffler
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
J. Leukoc. Biol.,
June 1, 2009;
85(6):
957 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hornakova, J. Staerk, Y. Royer, E. Flex, M. Tartaglia, S. N. Constantinescu, L. Knoops, and J.-C. Renauld
Acute Lymphoblastic Leukemia-associated JAK1 Mutants Activate the Janus Kinase/STAT Pathway via Interleukin-9 Receptor {alpha} Homodimers
J. Biol. Chem.,
March 13, 2009;
284(11):
6773 - 6781.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. James
The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases?
Hematology,
January 1, 2008;
2008(1):
69 - 75.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
